Lancet

• 

  Publication Venue For

  • Age-adjusted D-dimer cutoffs to guide anticoagulation in COVID-19 - Authors' reply..  398:1304. 2021
  • Singapore's health-care system: key features, challenges, and shifts..  398:1091-1104. 2021
  • Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial..  397:2253-2263. 2021
  • Urgent lessons from COVID 19: why the world needs a standing, coordinated system and sustainable financing for global research and development..  397:1229-1236. 2021
  • Addressing the global burden of hearing loss..  397:945-947. 2021
  • A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial..  397:695-703. 2021
  • Mavacamten for hypertrophic obstructive cardiomyopathy..  397:369. 2021
  • First-attempt success rate of video laryngoscopy in small infants (VISI): a multicentre, randomised controlled trial..  396:1905-1913. 2020
  • COVID-19 in Brazil: the headlines should be about science..  396:1803. 2020
  • Strategy, coordinated implementation, and sustainable financing needed for COVID-19 innovations..  396:1469-1471. 2020
  • Five insights from the Global Burden of Disease Study 2019..  396:1135-1159. 2020
  • Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019..  396:1160-1203. 2020
  • Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019..  396:1204-1222. 2020
  • Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019..  396:1223-1249. 2020
  • Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019..  396:1250-1284. 2020
  • Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial..  396:959-967. 2020
  • Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial..  396:759-769. 2020
  • Sex and gender: modifiers of health, disease, and medicine..  396:565-582. 2020
  • Recurrence of breast cancer after anaesthesia..  396:376. 2020
  • Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study..  396:27-38. 2020
  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study..  395:1907-1918. 2020
  • Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials..  395:1627-1639. 2020
  • Is the HScore useful in COVID-19?.  395:e83. 2020
  • Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial..  395:1444-1451. 2020
  • Chagas disease: still a neglected emergency?.  395:1113-1114. 2020
  • Antithrombotic treatment strategies after PCI..  395:866-867. 2020
  • From Hendra to Wuhan: what has been learned in responding to emerging zoonotic viruses..  395:e33-e34. 2020
  • Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial..  392:2705-2717. 2019
  • Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial..  394:2184-2196. 2019
  • Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial..  394:2012-2024. 2019
  • Time to revisit indications for cholecystectomy..  394:1803-1804. 2019
  • Improved patient selection for implantable defibrillators..  394:1302-1304. 2019
  • Parallel community solutions for cardiovascular risk reduction..  394:1207-1208. 2019
  • High-quality evidence to inform clinical practice..  394:633-634. 2019
  • Building evidence and measuring clinical outcomes for genomic medicine..  394:604-610. 2019
  • Family health history: underused for actionable risk assessment..  394:596-603. 2019
  • Opportunities, resources, and techniques for implementing genomics in clinical care..  394:511-520. 2019
  • Department of Error..  393:e44. 2019
  • A Lancet Commission to address the global burden of hearing loss..  393:2106-2108. 2019
  • Sham trials: benefits and risks for cardiovascular research and patients..  393:2104-2106. 2019
  • Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017..  393:1958-1972. 2019
  • Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology..  393:1045-1055. 2019
  • Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial..  393:1021-1032. 2019
  • Heart failure drug treatment..  393:1034-1044. 2019
  • Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials..  393:407-415. 2019
  • Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017..  392:1684-1735. 2018
  • Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017..  392:1736-1788. 2018
  • Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017..  392:1923-1994. 2018
  • Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017..  392:1859-1922. 2018
  • Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017..  392:1789-1858. 2018
  • Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017..  392:2091-2138. 2018
  • Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017..  392:1995-2051. 2018
  • Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial..  392:1519-1529. 2018
  • Age-related macular degeneration..  392:1147-1159. 2018
  • Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016..  392:1015-1035. 2018
  • Reimagining population health as convergence science..  392:367-368. 2018
  • Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)..  392:232-243. 2018
  • Assessment of functional capacity before major non-cardiac surgery: an international, prospective cohort study..  391:2631-2640. 2018
  • Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial..  391:2346-2355. 2018
  • Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016..  391:2236-2271. 2018
  • Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial..  391:1997-2007. 2018
  • Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies..  391:1513-1523. 2018
  • Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition..  391:1224-1236. 2018
  • NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial..  391:1174-1185. 2018
  • Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial..  391:850-859. 2018
  • Rifampicin for Staphylococcus aureus bacteraemia: give it ARREST..  391:634-636. 2018
  • Reducing health disparities: Bar Ilan Medical School's care transition service..  391:533-534. 2018
  • Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial..  391:205-218. 2018
  • Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial..  391:219-229. 2018
  • Secondary prevention shifts into second gear..  391:181-182. 2018
  • Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults..  390:2627-2642. 2017
  • Global hearing health care: new findings and perspectives..  390:2503-2515. 2017
  • Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial..  390:2160-2170. 2017
  • Department of Error..  390:e38. 2017
  • Innovating through "interesting times" in global health..  390:e33-e34. 2017
  • Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial..  390:1833-1842. 2017
  • A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial..  390:1737-1746. 2017
  • Department of Error..  390:e23. 2017
  • Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016..  390:1151-1210. 2017
  • Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016..  390:1260-1344. 2017
  • Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016..  390:1084-1150. 2017
  • Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016..  390:1423-1459. 2017
  • The oldest-old in China - Authors' reply..  390:847. 2017
  • Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015..  390:231-266. 2017
  • STREAM characterisation correction..  389:2102. 2017
  • Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015..  389:1885-1906. 2017
  • Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial..  389:1799-1808. 2017
  • ANTARCTIC: platelet function testing to adjust therapy..  389:1193. 2017
  • Enhanced terminal room disinfection and acquisition and infection caused by multidrug-resistant organisms and Clostridium difficile (the Benefits of Enhanced Terminal Room Disinfection study): a cluster-randomised, multicentre, crossover study..  389:805-814. 2017
  • Early goal-directed mobilisation after surgery - Authors' reply..  389:695-696. 2017
  • Department of Error..  389:e1. 2017
  • Department of Error..  389:e1. 2017
  • Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants..  389:37-55. 2017
  • Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial..  388:2895-2903. 2016
  • Assessment of economic vulnerability to infectious disease crises..  388:2443-2448. 2016
  • The effects of China's universal two-child policy..  388:1930-1938. 2016
  • Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015..  388:1659-1724. 2016
  • Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015..  388:1603-1658. 2016
  • Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015..  388:1545-1602. 2016
  • Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015..  388:1775-1812. 2016
  • Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015..  388:1459-1544. 2016
  • Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015..  388:1725-1774. 2016
  • Early, goal-directed mobilisation in the surgical intensive care unit: a randomised controlled trial..  388:1377-1388. 2016
  • Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial..  388:1183-1192. 2016
  • Rhythm control in atrial fibrillation..  388:829-840. 2016
  • IxCELL-DCM: rejuvenation for cardiac regenerative therapy?.  387:2362-2363. 2016
  • The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study..  387:2302-2311. 2016
  • Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials..  387:2026-2034. 2016
  • The Institute of Medicine: ensuring integrity and independence in scientific advice on health..  387:1686-1692. 2016
  • REGULATE-PCI trial--Author's reply..  387:1510-1511. 2016
  • Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants..  387:1513-1530. 2016
  • Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants..  387:1377-1396. 2016
  • Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial..  387:1178-1186. 2016
  • Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial..  387:661-670. 2016
  • A medical-toxicological view of tattooing..  387:395-402. 2016
  • Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial..  387:349-356. 2016
  • Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial..  387:127-135. 2016
  • Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial..  387:136-145. 2016
  • Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013..  386:2287-2323. 2015
  • Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition..  386:2145-2191. 2015
  • Radiation exposure in relation to the arterial access site used for diagnostic coronary angiography and percutaneous coronary intervention: a systematic review and meta-analysis..  386:2192-2203. 2015
  • Intracerebral haemorrhage, atrial fibrillation, and anticoagulation - Authors' reply..  386:1737. 2015
  • Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013..  386:743-800. 2015
  • Pharmacological and emerging therapies in the treatment of chronic angina..  386:691-701. 2015
  • Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs..  386:303-310. 2015
  • Tenofovir alafenamide for HIV infection: is less more?.  385:2559-2560. 2015
  • 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial..  385:2485-2491. 2015
  • 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial..  385:2477-2484. 2015
  • Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial..  385:2465-2476. 2015
  • Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)..  385:2363-2370. 2015
  • The theory and practice of imaging outcomes research..  385:2334-2335. 2015
  • Edoxaban and the need for outcomes-based NOAC dosing..  385:2232-2233. 2015
  • Aligning incentives to fulfil the promise of personalised medicine..  385:2118-2119. 2015
  • Financial contribution to global surgery: an analysis of 160 international charitable organisations..  385 Suppl 2:S52. 2015
  • Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials..  385:1397-1405. 2015
  • PHOTON-2: hope for patients with HIV and HCV co-infection?.  385:1052-1054. 2015
  • Time to treatment as a quality metric for acute STEMI care..  385:1056-1057. 2015
  • Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial..  385:956-965. 2015
  • Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013..  385:117-171. 2015
  • A new era in medical therapy for retinal degenerative disease?.  384:1482-1484. 2014
  • Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' reply..  384:1097-1098. 2014
  • Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013..  384:1005-1070. 2014
  • Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013..  384:980-1004. 2014
  • China's distinctive engagement in global health..  384:793-804. 2014
  • Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes..  383:2008-2017. 2014
  • Childhood cancer, endocrine disorders, and cohort studies..  383:1950-1952. 2014
  • Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis..  383:1059-1066. 2014
  • Stem-cell transplantation for chronic granulomatous disease..  383:390-392. 2014
  • Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study..  382:1714-1722. 2013
  • Treatment of age-related macular degeneration..  382:1230-1232. 2013
  • Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial..  382:605-613. 2013
  • What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention?.  382:633-643. 2013
  • Exercise for late-life depression? It depends..  382:4-5. 2013
  • CT scans in childhood and risk of leukaemia and brain tumours..  380:1737-1738. 2012
  • Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial..  380:1749-1758. 2012
  • Prediabetes and the risk of diabetes..  380:1225-1226. 2012
  • The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials..  380:581-590. 2012
  • Prevalence of chronic kidney disease in China..  380:213-214. 2012
  • Age-related macular degeneration..  379:1728-1738. 2012
  • Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data..  379:322-334. 2012
  • Haemopoietic stem-cell transplantation for systemic sclerosis..  379:219. 2012
  • Bronchoscopic lung-volume reduction with Exhale airway stents for emphysema (EASE trial): randomised, sham-controlled, multicentre trial..  378:997-1005. 2011
  • Antithrombin alternatives in STEMI..  378:643-645. 2011
  • Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial..  377:1409-1420. 2011
  • Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies..  377:1085-1095. 2011
  • Decompression illness..  377:153-164. 2011
  • Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials..  376:1670-1681. 2010
  • Mixed messages on systemic therapies for diabetic retinopathy..  376:1461. 2010
  • Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial..  376:1320-1328. 2010
  • Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial..  376:1233-1243. 2010
  • Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases..  376:922-927. 2010
  • Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial..  376:784-793. 2010
  • Tracking radiation exposure of patients..  376:754-755. 2010
  • Common genetic determinants of vitamin D insufficiency: a genome-wide association study..  376:180-188. 2010
  • Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies..  375:2215-2222. 2010
  • Tracking China's health reform..  375:1056-1058. 2010
  • The role of academic health science systems in the transformation of medicine..  375:949-953. 2010
  • Liver disease in pregnancy..  375:594-605. 2010
  • Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study..  375:283-293. 2010
  • C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis..  375:132-140. 2010
  • Second primary cancers in survivors of childhood cancer..  374:1484-1485. 2009
  • Standardised metrics for global surgical surveillance..  374:1113-1117. 2009
  • Albuminuria in chronic heart failure: prevalence and prognostic importance..  374:543-550. 2009
  • Key issues for global cardiovascular medicine..  374:508-510. 2009
  • Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial..  373:1958-1965. 2009
  • Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial..  373:1949-1957. 2009
  • Towards a common definition of global health..  373:1993-1995. 2009
  • The importance of VTE prevention after orthopaedic surgery..  373:1661-1662. 2009
  • Advancing care for acute heart failure--no time to relax..  373:1401-1402. 2009
  • Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study..  373:1429-1439. 2009
  • Enjoying and enduring: groups reading aloud for wellbeing..  373:1339-1340. 2009
  • Public disclosure of clinical research..  373:1319-1320. 2009
  • Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials..  373:1190-1197. 2009
  • Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial..  373:1097-1104. 2009
  • Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study..  373:919-928. 2009
  • Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study..  373:739-745. 2009
  • Combination HIV prevention..  372:1805-1806. 2008
  • Reform of how health care is paid for in China: challenges and opportunities..  372:1846-1853. 2008
  • Community-based newborn care in Bangladesh..  372:1541. 2008
  • Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya..  372:1555-1562. 2008
  • DIRECT new treatments for diabetic retinopathy..  372:1361-1363. 2008
  • Beta-blocker therapy in non-cardiac surgery..  372:1146-1147. 2008
  • The history and challenge of HIV prevention..  372:475-488. 2008
  • Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood..  371:2201-2212. 2008
  • Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial..  371:1839-1847. 2008
  • Waterboarding is not torture: a physician's response..  371:1838. 2008
  • Immunisation against poliomyelitis: moving forward..  371:1385-1387. 2008
  • Fenofibrate and diabetic retinopathy..  371:721-722. 2008
  • Appropriate prescribing in elderly people: how well can it be measured and optimised?.  370:173-184. 2007
  • Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study..  369:1947-1954. 2007
  • Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial..  369:907-919. 2007
  • Treatment of medically intractable cluster headache by occipital nerve stimulation: long-term follow-up of eight patients..  369:1099-1106. 2007
  • Sexual dysfunction in men and women with endocrine disorders..  369:597-611. 2007
  • Screening mammography at 40-49 years: regret or no regret?.  368:2035-2037. 2006
  • Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial..  368:1248-1253. 2006
  • Central nervous system injury associated with cardiac surgery..  368:694-703. 2006
  • Facilitated versus primary PCI for acute myocardial infarction..  367:1813. 2006
  • Trial summaries on results databases and journal publication..  367:1635-1636. 2006
  • Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial..  367:29-35. 2006
  • Are the clinical effects of homoeopathy placebo effects?.  366:2081-2082. 2005
  • Are the clinical effects of homoeopathy placebo effects?.  366:2082-2083. 2005
  • Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial..  366:2005-2011. 2005
  • The MANTRA II study..  366:1769. 2005
  • Blood vessels engineered from human cells..  366:891-892. 2005
  • Intermittent preventive malaria treatment in Tanzanian infants..  366:545. 2005
  • Music, imagery, touch, and prayer as adjuncts to interventional cardiac care: the Monitoring and Actualisation of Noetic Trainings (MANTRA) II randomised study..  366:211-217. 2005
  • Blood vessels engineered from human cells..  365:2122-2124. 2005
  • A man with chest pain and glomerulonephritis..  365:2062. 2005
  • CT colonography for detection of colon polyps and cancer..  365:1464-1465. 2005
  • Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison..  365:305-311. 2005
  • MRC CLASICC trial..  366:713. 2005
  • How much of China's success in tuberculosis control is really due to DOTS?.  364:391-392. 2004
  • A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4)..  363:852-859. 2004
  • International differences in evolution of early discharge after acute myocardial infarction..  363:511-517. 2004
  • Neuroprotective therapy for acute ischaemic stroke: down, but not out..  363:414-415. 2004
  • Selective decontamination of digestive tract in intensive care..  362:2117-2118. 2003
  • Does informed consent to research require comprehension?.  362:2016-2018. 2003
  • When clinical medicine collides with religion..  362 Suppl:s28-s29. 2003
  • Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis..  362:1605-1611. 2003
  • The CHARM programme..  362:1675-1676. 2003
  • Depression as risk factor for mortality after coronary artery bypass surgery..  362:1499-1500. 2003
  • Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial..  362:777-781. 2003
  • Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial..  362:772-776. 2003
  • Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial..  362:767-771. 2003
  • Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme..  362:759-766. 2003
  • Depression as a risk factor for mortality after coronary artery bypass surgery..  362:604-609. 2003
  • Antifibrinolytic therapy: new data and new concepts..  376:3-4. 2010
  • Funding flows to global surgery: an analysis of contributions from the USA. 2015
  • Mapping the playing field-a novel web-based strategy to identify non-governmental actors in global surgery. 2015
  • Diabetic retinopathy. 2010
  • Pancreatic cancer. 2004